Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis.
Jörn Markus SchattenbergJeffrey Victor LazarusPhilip N NewsomeLawrence SerfatyAlessio AghemoSalvador AugustinEmmanuel A TsochatzisVictor De LedinghenElisabetta BugianesiManuel RomeroHeike BantelStephen D RyderJerome BoursierVincent LeroyJavier CrespoLaurent CasteraLefteris FlorosVincenzo AtellaJorge Mestre-FerrandizRachel ElliottAchim KautzAlice MorganSally HartmanisSharad VasudevanLynne PezzulloAldo TrylesinskiSandrine CureVictoria HigginsVlad RatziuPublished in: Liver international : official journal of the International Association for the Study of the Liver (2021)
This study found that the majority of economic and wellbeing costs of NASH are experienced in late disease stages. Earlier diagnosis and care of NASH patients could reduce future healthcare costs.